GLP-1 receptor agonists such as the popular weight loss/diabetes therapies Mounjaro, developed by Eli Lilly (NYSE:LLY), and Ozempic, developed by Novo Nordisk (NVO), can reduce cancer risk, according… [+85 chars]
GLP-1 drugs are linked to lower cancer risk: study (NVO:NYSE) - Seeking Alpha
Novo Nordisk's (NVO) Ozempic, Eli Lilly's (LLY) Mounjaro and other GLP-1 drugs may lower cancer risk in obese patients, according to a new study. Read more here.
By:Dulan Lokuwithana
Source:Seeking Alpha
Published:
Related News
Protein is so last year. Why fiber is the next big thing - CNN
Move over, protein. Fiber is on pace to be the next “it” nutrient of the year.
CNN•Jordan Valinsky
Scientists call for urgent action as dangerous amoebas spread globally - ScienceDaily
Scientists are warning that a little-known group of microbes called free-living amoebae may pose a growing global health threat. Found in soil and water, some species can survive extreme heat, chlorine, and even modern water systems—conditions that kill most …
Science Daily
Officials Report Outbreak of Deadly Nipah Virus, Which Has No Cure - AOL.com
Nipah is a zoonotic virus with a high mortality rate
PEOPLE•Charlotte Phillipp